ribociclib

Overview

Ribociclib is a CDK4/6 inhibitor that blocks G1-to-S cell cycle progression. It was evaluated in hepatocellular carcinoma (HCC) in the context of RB1 loss and CDKN2A deletion, which occur in 4–5% and 2–5% of HCCs respectively.

Evidence in the corpus

• Mentioned in comprehensive HCC molecular landscape review as a CDK4/6 inhibitor under evaluation in the context of RB1 LOF (4%) and homozygous deletion (5%) and CDKN2A deletions in HCC PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.